G9a was shown to accumulate under hypoxic conditions (113), and as AML LSCs are known to reside in hypoxic BM niches, therapeutic targeting of G9a may efficiently eliminate AML LSCs (Table 1). This evidence concerns the gene EHMT2 and acute myeloid leukemia.